MedTrace Logo

Comparative Study of Gene-activated Bone Substitute and Xenogenic Bone Matrix in Alveolar Ridge Augmentation

NCT04511689 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2020-08-13

No results posted yet for this study

Summary

The study aim is to compare the effectiveness of two bone substitutes, the gene-activated bone substitute based on octacalcium phosphate and plasmid DNA encoding VEGFA gene and xemogenic deproteinized bone matrix, mixed with shredded autobone in vertical and horizontal augmentation of alveolar ridge before dental implantation

Conditions

  • Alveolar Bone Loss
  • Alveolar Ridge Pathology | Gingiva | Dental

Interventions

DEVICE

gene-activated bone substitute mixed with autobone

gene-activated bone substitute based on octacalcium phosphate and plasmid DNA encoding VEGFA gene mixed with autobone

Sponsors & Collaborators

  • Moscow State University of Medicine and Dentistry

    collaborator OTHER

  • Histograft Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Grigory Volozhin, MD, PhD · A.I. Evdokimov Moscow State University of Medicine and Dentistry

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2021-07-01
Completion
2021-08-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04511689 on ClinicalTrials.gov